Last reviewed 2026-05-14 · How we verify

FLU Q-PAN H5N8 375_B

GlaxoSmithKline · Phase 1 active Biologic

FLU Q-PAN H5N8 375_B is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 1 development.

At a glance

Generic name	FLU Q-PAN H5N8 375_B
Sponsor	GlaxoSmithKline
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

FLU Q-PAN H5N8 375_B CI brief — competitive landscape report
FLU Q-PAN H5N8 375_B updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI

Frequently asked questions about FLU Q-PAN H5N8 375_B

What is FLU Q-PAN H5N8 375_B?

FLU Q-PAN H5N8 375_B is a Biologic drug developed by GlaxoSmithKline.

Who makes FLU Q-PAN H5N8 375_B?

FLU Q-PAN H5N8 375_B is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What development phase is FLU Q-PAN H5N8 375_B in?

FLU Q-PAN H5N8 375_B is in Phase 1.

Manufacturer: GlaxoSmithKline — full pipeline
Compare: FLU Q-PAN H5N8 375_B vs similar drugs
Pricing: FLU Q-PAN H5N8 375_B cost, discount & access